Publications by authors named "Alaa Abu Sayf"
Article Synopsis
- The study investigates the impact of tocilizumab, an IL-6 targeting therapy, on patients with COVID-19 related ARDS and low urine output, which together are linked to higher mortality rates.
- It reviews data from 128 adult patients in an ICU setting, finding that 80% had low urine output at intubation, and that tocilizumab use was linked to improved survival.
- The results suggest that while several factors relate to mortality, only tocilizumab was independently associated with better survival outcomes, emphasizing the need for further studies on urine output and IL-6 targeted treatments in ARDS management.
Patients with sickle cell disease are at risk of vaso-occlusive crises including acute chest syndrome (ACS) and pulmonary hypertension. ACS is a life-threatening complication of sickle cell disease and is associated with increased morbidity and mortality. It is known that pulmonary pressures increase during episodes of acute chest syndrome and may lead to acute right ventricular failure leading to increased morbidity and mortality.
View Article and Find Full Text PDFObjectives: To investigate the differences in clinical course, ventilator mechanics, and outcomes of patients with coronavirus disease 2019 secondary to acute respiratory distress syndrome infection compared with a historical cohort of acute respiratory distress syndrome.
Design: Comparative case-control study.
Setting: Multicenter, comprehensive tertiary healthcare facility in Detroit, MI.
Background: Majority of our computed tomography-pulmonary angiography (CTPA) scans report negative findings. We hypothesized that suboptimal reliance on diagnostic algorithms contributes to apparent overuse of this test.
Methods: A retrospective review was performed on 2031 CTPA cases in a large hospital system.